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SUMMARy – The aim of the study was to determine the prevalence of pseudobulbar affect 
(PBA) in patients with multiple sclerosis (MS) and to analyze the link between PBA and patient 
age, sex, clinical course of MS, disease duration and degree of disability. The study was conduc-
ted on 79 MS patients that underwent inpatient rehabilitation at the Lipik Special Hospital for 
Medical Rehabilitation in the period from August 15, 2014 to February 15, 2015. PBA is a term 
used for an emotional disinhibition syndrome characterized by sudden and involuntary episodes of 
crying or laughing which are not in proportion to the stimulus applied or occur without stimulus. 
The condition can be present in patients with various neurological disorders, such as amyotrophic 
lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, patients having recovered from stroke, or 
following traumatic brain injury. The estimated prevalence in patients with MS ranges from 10% to 
46.2%. As a measuring instrument in the study, we used the Center for Neurologic Study-Lability 
Scale (CNS-LS), where a sum ≥17 denoted positive finding. The total number of respondents was 79, 
of which 33 (41.8%) met the CNS-LS criteria for the diagnosis of PBA. There was no statistically 
significant correlation between PBA, age and degree of disability, although PBA was more common 
in women and in patients with a secondary progressive form of the disease. We found that 42.4% of 
respondents with positive CNS-LS criteria for PBA did not inform their neurologist on the presence 
of sudden mood changes. The high frequency of PBA and the fact that a significant proportion of 
patients did not inform the neurologist on their affective disturbances call for an active approach to 
diagnosis and treatment.
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Introduction 
Pseudobulbar affect (PBA) is a term used for an 
emotional disinhibition syndrome characterized by 
sudden and involuntary episodes of crying or laugh-
ing, where such episodes are not in proportion to the 
stimulus applied or occur without stimulus1. Although 
the pathophysiology has not yet been fully elucidated, 
PBA has been linked to lesions in the frontal lobes 
and descending pathways to the brain stem, the base 
of the pons and cerebellum, which in turn leads to 
disorders in the system that is believed to participate 
in the motor control of emotional expression2-4. The 
synonyms frequently used for pseudobulbar affect 
in scientific literature are the terms of involuntary 
emotional expression disorder, emotional lability, 
emotional incontinence, and pathological laughing 
and crying5, which makes it difficult to estimate 
the prevalence of the syndrome2,6. It is thought that 
PBA is inadequately identified in clinical practice, 
and may be misdiagnosed as a mood disorder such 
as depression5,7-9. PBA and depressive disorders may 
co-exist, but recent research has shown a high inci-
dence of depression in patients with PBA9,10-17. The 
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condition may be present in a variety of neurological 
disorders. It is most common in patients with amyo-
trophic lateral sclerosis (44.8%-60%)18-21, Alzheimer’s 
disease (29.3%-39%)11,18, in persons having recovered 
from stroke (11%-53%)14,18,22-24, those with Parkinson’s 
disease (4.7%-42.5%)9,12,13,17,18, and after a traumatic 
brain injury (5%-52.4%)18,25,26. In patients with mul-
tiple sclerosis (MS), the estimated prevalence is 10%-
46.2%6,18,27. Given that the studies use different crite-
ria for diagnosing the syndrome, the prevalence varies 
significantly, even in terms of individually analyzed 
diseases. More recent studies have used the Center for 
Neurologic Study-Lability Scale (CNS-LS), validated 
for patients suffering from amyotrophic lateral sclero-
sis and MS, for evaluation and quantification of PBA 
symptoms28,29. The CNS-LS consists of a scale for 
laughter (4 questions) and crying (3 questions). Each 
answer is scored 1 to 5 (1 = never through 5 = almost 
always), depending on the frequency of the symptoms 
tested. The total sum varies from 7 (no symptoms) to 
35 (maximum expressed symptoms). When validating 
a scale for MS patients, the recommended threshold 
is ≥17 for establishing a diagnosis of PBA29. In the 
validation process, a threshold ≥17 coincided with a 
clinical diagnosis in 89% of cases, accompanied by a 
sensitivity of 0.94 and specificity of 0.83. According 
to the recommendation of the American Academy 
of Neurology (AAN), the CNS-LS can be used for 
screening the existence of PBA30, where the recom-
mendation is based on a study in which the valida-
tion was conducted29. In some studies, estimates of 
the prevalence of PBA in MS patients are considered 
a positive finding if the sum is ≥136,18, which is the 
validated threshold for the diagnosis of PBA in those 
suffering from amyotrophic lateral sclerosis. Also, a 
more restrictive threshold of ≥216,18 has been used 
for moderate and severe forms of the disorder, for 
which, however, validation has not been conducted. 
A threshold of ≥13 on the CNS-LS for patients with 
MS has a sensitivity of 0.96 and specificity of 0.55 
for the diagnosis of PBA, which also leads to false-
positive findings29. The aim of the study was to de-
termine the prevalence of PBA in MS patients and 
analyze the relationship between PBA and patient 
age, sex, clinical form of MS, and time elapsed from 
MS diagnosis.
Patients and Methods
The study included 79 patients with MS that un-
derwent inpatient rehabilitation at the Lipik Special 
Hospital for Medical Rehabilitation in the period 
from August 15, 2014 to February 15, 2015. Partici-
pating in the study were patients older than 18 and di-
agnosed with MS according to the revised McDonald 
criteria31. The exclusion criterion was serious cognitive 
impairment, and accordingly, five patients were not 
included in the study. Data on patient age, sex, clini-
cal course of MS, and time elapsed from MS diagno-
sis were collected. The diagnosis of PBA was made 
by use of the CNS-LS28, where a sum ≥17 denoted 
positive finding. The degree of disability for all study 
subjects was based on the Expanded Disability Status 
Scale (EDSS)32, and assessment of cognitive status 
was performed using the Mini Mental Status Exam 
(MMSE)33. Patients with a CNS-LS sum ≥17 were 
asked whether they had informed their neurologist on 
the sudden and involuntary mood changes. The study 
was approved by the Hospital Ethics Committee and 
patients were required to provide written consent for 
their participation.
Statistical analysis was performed using the SOFA 
Stats. Comparison of the variables was conducted 
using the Student’s T-test and Pearson’s correlation 
test.
Results 
The study included 79 patients, 48 (60.8%) female 
and 31 (39.2%) male, mean age 48.9 years, age range 
21-71 years. The mean time elapsed from MS diagno-
sis was 11.5 years (range, 6 months to 32 years). The 
relapsing-remitting course of the disease (RRMS) 
was experienced by 42 (53%) and secondary progres-
sive MS (SPMS) by 37 (47%) patients. The mean 
EDSS was 4.7, range 1 to 9. Out of 79 study patients, 
33 (41.8%) patients were diagnosed with PBA. Study 
patients were divided into two groups according to 
the presence/absence of PBA (Table 1). There were no 
statistically significant differences between the groups 
with and without PBA according to age (P=0.915), 
disease duration (P=0.374) and degree of disability 
measured by EDSS (P=0.6). The PBA positive group 
showed a significantly higher female predominance 
(P=0.066). The distribution of PBA prevalence in the 
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two clinical courses of MS indicated it to be higher 
in patients with SPMS (19 of 37 or 51.4% were PBA 
positive; 18 of 37 or 48.6% were PBA negative) than in 
those with RRMS (14 of 42 or 33.3% were PBA posi-
tive; 28 of 42 or 66.7% were PBA negative) (Fig. 1). 
Furthermore, 14 of 33 PBA positive patients (42.4%) 
had not informed their neurologist on the presence of 
sudden mood changes.
Discussion
In our study, the prevalence of PBA in MS pa-
tients was 41.8%, and the diagnosis of PBA was based 
on the CNS-LS sum ≥17. We used this threshold 
because it was validated for patients with MS29. The 
prevalence of PBA in patients with MS varies sig-
nificantly in published studies, ranging from 10% 
to 46.2%6,18,27; however, different thresholds on the 
CNS-LS and different measuring instruments were 
used on determining the prevalence rates. In the study 
by Feinstein et al., the prevalence of PBA was 10%27, 
and the measuring instrument used was the Patho-
logical Laughter and Crying Scale (PLACS)15. Work 
et al. have estimated that the prevalence of PBA in 
patients with MS was 46.2% based on the CNS-LS 
and using a threshold ≥13, and 9.8% when a sum ≥21 
was used as the threshold6. In the PRISM study18, the 
prevalence of PBA was 45.8% with a threshold on the 
CNS-LS ≥13 and 12.0% with a threshold ≥21. When 
we used a sum ≥13 on the CNS-LS as the threshold 
for diagnosing PBA in our study, the prevalence was 
51.9%. In none of the earlier studies was the sum ≥17 
on the CNS-LS used as the threshold for diagnosing 
PBA, hence a comparison of the prevalence rate with 
our study using this threshold is not possible.
A limitation of the study was the fact that using 
the CNS-LS does not set a definitive diagnosis of 
PBA, but provides screening instead. Therefore, posi-
tive patients require further neurological and psychi-
atric assessment. Furthermore, we did not evaluate 
the possible presence of psychiatric disorders, such 
as depression or bipolar disorder. Also, some of the 
symptoms described using the CNS-LS (e.g., crying) 
may be associated with the possible existence of an-
other psychiatric disorder. The same limitation applies 
to other studies6,18,27.
Statistically, PBA was more significantly present 
in women. In the PRISM study18, PBA was also more 
common in women, and given that other factors that 
may have affected the difference in the prevalence rate 
depending on sex were not analyzed in these studies, 
the reason for the difference remains unknown.
In our study, there were no significant differences 
between the patient groups with and without PBA ac-
cording to age and disease duration. The prevalence 
of the secondary progressive course of the disease was 
higher in the PBA positive group as compared with 
the PBA negative group. The same finding has been 
reported by Feinstein et al.27, while other studies did 
not analyze the relationship between PBA and age, 
disease duration, degree of disability, and clinical 
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Fig. 1. Prevalence of PBA positive and PBA negative 
patients in two clinical courses of multiple sclerosis.
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courses of the disease6,18. Considering that patients 
with the secondary progressive course of the disease 
due to pathological process have a larger number of 
cerebral regions affected, the higher prevalence in this 
group could be explained by the fact that those cen-
tral nervous system areas that participate in the motor 
control of emotional expression are also more likely to 
be affected.
The absence of a link between the incidence of PBA 
and neurological deficit measured using EDSS could 
be due to the fact that on determining the degree of 
deficit measured by EDSS, the symptoms not linked 
to the affected brain regions the lesions of which cause 
PBA are also summed, e.g., the degree of sphincter 
control and sensory deficit.
Slightly less than half of the study patients (42.4%) 
diagnosed with PBA had not informed the neurolo-
gist on their emotional disorders.
Conclusions 
In the present study, the prevalence of PBA based 
on the CNS-LS questionnaire in patients with MS 
was 41.8%. Given the high prevalence and the fact 
that a large proportion of patients did not inform the 
neurologist on their emotional disorders, there is a 
need to actively look for PBA symptoms in patients 
with MS.
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Sažetak
PSEUDOBULBARNI AFEKT KOD OBOLJELIH OD MULTIPLE SKLEROZE
V. Vidović, M. Časar Rovazdi, O. Kraml i V. Bašić Kes
Cilj rada je bio odrediti učestalost pseudobulbarnog afekta (PBA) kod oboljelih od multiple skleroze (MS) i analizirati 
povezanost PBA s dobi bolesnika, spolom, kliničkim oblikom MS, trajanjem bolesti i stupnjem onesposobljenosti. Stu-
dija je obuhvatila 79 oboljelih od MS koji su u razdoblju od 15. kolovoza 2014. do 15. veljače 2015. provodili stacionarnu 
rehabilitaciju u Specijalnoj bolnici za medicinsku rehabilitaciju Lipik. PBA je naziv za sindrom dezinhibicije emocionalne 
ekspresije obilježen iznenadnim i nevoljnim epizodama plača ili smijeha koje nisu u razmjeru s primijenjenim podražajem 
ili se javljaju bez njega. Može biti prisutan kod oboljelih od različitih neuroloških bolesti poput amiotrofične lateralne 
skleroze, Alzheimerove bolesti, Parkinsonove bolesti, kod osoba nakon preboljelog moždanog udara i nakon traumatskog 
oštećenja mozga. Procijenjena učestalost kod oboljelih od MS kreće se od 10% do 46,2%. Kao mjerni instrument u istra-
živanju koristili smo ljestvicu CNS-LS (Center for Neurologic Study-Lability Scale), pričem je zbroj ≥17 značio pozitivan 
nalaz. Ukupan broj ispitanika bio je 79, od kojih je 33 (41,8%) ispunilo kriterije CNS-LS za dijagnozu PBA. Nije nađena 
statistički značajna povezanost između PBA, dobi i stupnja onesposobljenosti, dok je PBA bio češći kod žena i oboljelih od 
sekundarno progresivnog oblika bolesti. Utvrđeno je da 42,4% ispitanika s pozitivnim kriterijima CNS-LS za PBA nije 
obavijestilo neurologa o prisutnim naglim promjenama u raspoloženju. Visoka učestalost PBA i činjenica da značajan udio 
oboljelih ne iznosi neurologu smetnje u afektivnoj sferi zahtijeva aktivan pristup u dijagnostici i liječenju.
Ključne riječi: Multipla skleroza – komplikacije; Pseudobulbarni afekt; Ljestvica CNS-LS 
